{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,12]],"date-time":"2026-05-12T01:22:46Z","timestamp":1778548966967,"version":"3.51.4"},"reference-count":68,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2014,9,1]],"date-time":"2014-09-01T00:00:00Z","timestamp":1409529600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2018,9,1]],"date-time":"2018-09-01T00:00:00Z","timestamp":1535760000000},"content-version":"vor","delay-in-days":1461,"URL":"https:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Kidney International"],"published-print":{"date-parts":[[2014,9]]},"DOI":"10.1038\/ki.2014.69","type":"journal-article","created":{"date-parts":[[2014,3,26]],"date-time":"2014-03-26T14:00:12Z","timestamp":1395842412000},"page":"625-637","source":"Crossref","is-referenced-by-count":43,"title":["No significant effect of angiotensin II receptor blockade on intermediate cardiovascular end points in hemodialysis patients"],"prefix":"10.1016","volume":"86","author":[{"given":"Christian D.","family":"Peters","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Krista D.","family":"Kjaergaard","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jens D.","family":"Jensen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kent L.","family":"Christensen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Charlotte","family":"Strandhave","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ida N.","family":"Tietze","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marija K.","family":"Novosel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bo M.","family":"Bibby","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lars T.","family":"Jensen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Erik","family":"Sloth","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bente","family":"Jespersen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1038\/ki.2014.69_bb0010","doi-asserted-by":"crossref","first-page":"1782","DOI":"10.1001\/jama.2009.1488","article-title":"Cardiovascular and noncardiovascular mortality among patients starting dialysis","volume":"302","author":"de Jager","year":"2009","journal-title":"JAMA"},{"key":"10.1038\/ki.2014.69_bb0015","doi-asserted-by":"crossref","first-page":"1009","DOI":"10.1016\/S0140-6736(09)60212-9","article-title":"Effect of lowering blood pressure on cardiovascular events and mortality in patients on dialysis: a systematic review and meta-analysis of randomised controlled trials","volume":"373","author":"Heerspink","year":"2009","journal-title":"Lancet"},{"key":"10.1038\/ki.2014.69_bb0020","doi-asserted-by":"crossref","first-page":"1213","DOI":"10.1161\/CIRCULATIONAHA.105.595496","article-title":"Differential impact of blood pressure-lowering drugs on central aortic pressure and clinical outcomes: principal results of the Conduit Artery Function Evaluation (CAFE) study","volume":"113","author":"Williams","year":"2006","journal-title":"Circulation"},{"key":"10.1038\/ki.2014.69_bb0025","doi-asserted-by":"crossref","first-page":"922","DOI":"10.1161\/hy1001.095774","article-title":"Improvement in blood pressure, arterial stiffness and wave reflections with a very-low-dose perindopril\/indapamide combination in hypertensive patient: a comparison with atenolol","volume":"38","author":"Asmar","year":"2001","journal-title":"Hypertension"},{"key":"10.1038\/ki.2014.69_bb0030","doi-asserted-by":"crossref","first-page":"1314","DOI":"10.1161\/HYPERTENSIONAHA.109.148999","article-title":"Amlodipine-valsartan combination decreases central systolic blood pressure more effectively than the amlodipine-atenolol combination: the EXPLOR study","volume":"55","author":"Boutouyrie","year":"2010","journal-title":"Hypertension"},{"key":"10.1038\/ki.2014.69_bb0035","doi-asserted-by":"crossref","first-page":"735","DOI":"10.1161\/hy0202.098325","article-title":"Central pulse pressure and mortality in end-stage renal disease","volume":"39","author":"Safar","year":"2002","journal-title":"Hypertension"},{"key":"10.1038\/ki.2014.69_bb0040","doi-asserted-by":"crossref","first-page":"2434","DOI":"10.1161\/01.CIR.99.18.2434","article-title":"Impact of aortic stiffness on survival in end-stage renal disease","volume":"99","author":"Blacher","year":"1999","journal-title":"Circulation"},{"key":"10.1038\/ki.2014.69_bb0045","doi-asserted-by":"crossref","first-page":"153","DOI":"10.2215\/CJN.05120610","article-title":"Prognostic value of aortic stiffness and calcification for cardiovascular events and mortality in dialysis patients: outcome of the Calcification Outcome in Renal Disease (CORD) Study","volume":"6","author":"Verbeke","year":"2011","journal-title":"Clin J Am Soc Nephrol"},{"key":"10.1038\/ki.2014.69_bb0050","doi-asserted-by":"crossref","first-page":"2588","DOI":"10.1093\/eurheartj\/ehl254","article-title":"Expert consensus document on arterial stiffness: methodological issues and clinical applications","volume":"27","author":"Laurent","year":"2006","journal-title":"Eur Heart J"},{"key":"10.1038\/ki.2014.69_bb0055","doi-asserted-by":"crossref","first-page":"866","DOI":"10.1053\/j.ajkd.2005.02.022","article-title":"Low doses of losartan and trandolapril improve arterial stiffness in hemodialysis patients","volume":"45","author":"Ichihara","year":"2005","journal-title":"Am J Kidney Dis"},{"key":"10.1038\/ki.2014.69_bb0060","doi-asserted-by":"crossref","first-page":"551","DOI":"10.1093\/ndt\/gfp395","article-title":"NT-proBNP, fluid volume overload and dialysis modality are independent predictors of mortality in ESRD patients","volume":"25","author":"Paniagua","year":"2010","journal-title":"Nephrol Dial Transplant"},{"key":"10.1038\/ki.2014.69_bb0065","doi-asserted-by":"crossref","first-page":"548","DOI":"10.1038\/sj.ki.5002087","article-title":"N-terminal pro brain natriuretic peptide predicts mortality in patients with end-stage renal disease in hemodialysis","volume":"71","author":"Madsen","year":"2007","journal-title":"Kidney Int"},{"key":"10.1038\/ki.2014.69_bb0070","doi-asserted-by":"crossref","first-page":"350","DOI":"10.1111\/j.1365-2362.2007.01785.x","article-title":"Cardiac biomarkers and survival in haemodialysis patients","volume":"37","author":"Sommerer","year":"2007","journal-title":"Eur J Clin Invest"},{"key":"10.1038\/ki.2014.69_bb0075","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1038\/ki.1995.22","article-title":"Clinical and echocardiographic disease in patients starting end-stage renal disease therapy","volume":"47","author":"Foley","year":"1995","journal-title":"Kidney Int"},{"key":"10.1038\/ki.2014.69_bb0080","doi-asserted-by":"crossref","first-page":"286","DOI":"10.1038\/ki.1989.192","article-title":"Impact of left ventricular hypertrophy on survival in end-stage renal disease","volume":"36","author":"Silberberg","year":"1989","journal-title":"Kidney Int"},{"key":"10.1038\/ki.2014.69_bb0085","doi-asserted-by":"crossref","first-page":"623","DOI":"10.2215\/CJN.07831109","article-title":"Cardiovascular effects of angiotensin converting enzyme inhibition or angiotensin receptor blockade in hemodialysis: a meta-analysis","volume":"5","author":"Tai","year":"2010","journal-title":"Clin J Am Soc Nephrol"},{"key":"10.1038\/ki.2014.69_bb0090","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1097\/MAJ.0b013e318249d387","article-title":"Angiotensin receptor blockers reduce left ventricular hypertrophy in dialysis patients: a meta-analysis","volume":"345","author":"Yang","year":"2013","journal-title":"Am J Med Sci"},{"key":"10.1038\/ki.2014.69_bb0095","doi-asserted-by":"crossref","first-page":"1912","DOI":"10.1056\/NEJM199212313272704","article-title":"Sympathetic overactivity in patients with chronic renal failure","volume":"327","author":"Converse","year":"1992","journal-title":"N Engl J Med"},{"key":"10.1038\/ki.2014.69_bb0100","doi-asserted-by":"crossref","first-page":"1354","DOI":"10.1161\/hc1102.105261","article-title":"Plasma norepinephrine predicts survival and incident cardiovascular events in patients with end-stage renal disease","volume":"105","author":"Zoccali","year":"2002","journal-title":"Circulation"},{"key":"10.1038\/ki.2014.69_bb0105","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1111\/sdi.12093","article-title":"Sympathetic nervous system function and dysfunction in chronic hemodialysis patients","volume":"26","author":"Rubinger","year":"2013","journal-title":"Semin Dial"},{"key":"10.1038\/ki.2014.69_bb0110","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1097\/01.ASN.0000045049.72965.B7","article-title":"Enalapril and losartan reduce sympathetic hyperactivity in patients with chronic renal failure","volume":"14","author":"Klein","year":"2003","journal-title":"J Am Soc Nephrol"},{"key":"10.1038\/ki.2014.69_bb0115","doi-asserted-by":"crossref","first-page":"2507","DOI":"10.1093\/ndt\/gfl293","article-title":"Candesartan, an angiotensin II type-1 receptor blocker, reduces cardiovascular events in patients on chronic haemodialysis - a randomized study","volume":"21","author":"Takahashi","year":"2006","journal-title":"Nephrol Dial Transplant"},{"key":"10.1038\/ki.2014.69_bb0120","doi-asserted-by":"crossref","first-page":"501","DOI":"10.1053\/j.ajkd.2008.04.031","article-title":"Effect of angiotensin receptor blockers on cardiovascular events in patients undergoing hemodialysis: an open-label randomized controlled trial","volume":"52","author":"Suzuki","year":"2008","journal-title":"Am J Kidney Dis"},{"key":"10.1038\/ki.2014.69_bb0125","doi-asserted-by":"crossref","first-page":"1701","DOI":"10.1016\/j.jacc.2010.03.105","article-title":"Effects of telmisartan added to angiotensin-converting enzyme inhibitors on mortality and morbidity in hemodialysis patients with chronic heart failure a double-blind, placebo-controlled trial","volume":"56","author":"Cice","year":"2010","journal-title":"J Am Coll Cardiol"},{"key":"10.1038\/ki.2014.69_bb0130","doi-asserted-by":"crossref","first-page":"1318","DOI":"10.1038\/sj.ki.5001657","article-title":"Prevention of cardiovascular events in end-stage renal disease: results of a randomized trial of fosinopril and implications for future studies","volume":"70","author":"Zannad","year":"2006","journal-title":"Kidney Int"},{"key":"10.1038\/ki.2014.69_bb0135","doi-asserted-by":"crossref","first-page":"1579","DOI":"10.1093\/ndt\/gfs590","article-title":"Effects of angiotensin receptor blockade (ARB) on mortality and cardiovascular outcomes in patients with long-term haemodialysis: a randomized controlled trial","volume":"28","author":"Iseki","year":"2013","journal-title":"Nephrol Dial Transplant"},{"key":"10.1038\/ki.2014.69_bb0140","doi-asserted-by":"crossref","first-page":"478","DOI":"10.1053\/j.ajkd.2005.11.024","article-title":"Effect of ramipril on left ventricular mass in normotensive hemodialysis patients","volume":"47","author":"Yu","year":"2006","journal-title":"Am J Kidney Dis"},{"key":"10.1038\/ki.2014.69_bb0145","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1038\/jhh.2010.42","article-title":"Systolic blood pressure and mortality in prevalent haemodialysis patients in the HEMO study","volume":"25","author":"Chang","year":"2011","journal-title":"J Hum Hypertens"},{"key":"10.1038\/ki.2014.69_bb0150","doi-asserted-by":"crossref","first-page":"2147","DOI":"10.1111\/j.1523-1755.2000.00388.x","article-title":"Importance of blood pressure control in hemodialysis patient survival","volume":"58","author":"Mazzuchi","year":"2000","journal-title":"Kidney Int"},{"key":"10.1038\/ki.2014.69_bb0155","first-page":"A4602","article-title":"Renal and cardiovascular effects of irbesartan in dialysis patients - a randomized controlled trial protocol (SAFIR study)","volume":"60","author":"Peters","year":"2013","journal-title":"Dan Med J"},{"key":"10.1038\/ki.2014.69_bb0160","unstructured":"KDOQI Clinical Practice Guidelines for Cardiovascular Disease in Dialysis Patients http:\/\/www.kidney.org\/professionals\/KDOQI\/guidelines_commentaries.cfm"},{"key":"10.1038\/ki.2014.69_bb0165","doi-asserted-by":"crossref","first-page":"2786","DOI":"10.1161\/01.CIR.90.6.2786","article-title":"Cardiac hypertrophy, aortic compliance, peripheral resistance, and wave reflection in end-stage renal disease. Comparative effects of ACE inhibition and calcium channel blockade","volume":"90","author":"London","year":"1994","journal-title":"Circulation"},{"key":"10.1038\/ki.2014.69_bb0170","doi-asserted-by":"crossref","first-page":"1139","DOI":"10.1097\/00004872-199609000-00015","article-title":"Antihypertensive effects and arterial haemodynamic alterations during angiotensin converting enzyme inhibition","volume":"14","author":"London","year":"1996","journal-title":"J Hypertens"},{"key":"10.1038\/ki.2014.69_bb0175","first-page":"59","article-title":"A selective angiotensin receptor antagonist, Valsartan, produced regression of left ventricular hypertrophy associated with a reduction of arterial stiffness","volume":"19","author":"Suzuki","year":"2003","journal-title":"Adv Perit Dial"},{"key":"10.1038\/ki.2014.69_bb0180","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1681\/ASN.V131177","article-title":"Contribution of volume overload and angiotensin II to the increased pulse wave velocity of hemodialysis patients","volume":"13","author":"Tycho Vuurmans","year":"2002","journal-title":"J Am Soc Nephrol"},{"key":"10.1038\/ki.2014.69_bb0185","doi-asserted-by":"crossref","first-page":"434","DOI":"10.1161\/01.HYP.38.3.434","article-title":"Arterial wave reflections and survival in end-stage renal failure","volume":"38","author":"London","year":"2001","journal-title":"Hypertension"},{"key":"10.1038\/ki.2014.69_bb0190","doi-asserted-by":"crossref","first-page":"2859","DOI":"10.1093\/ndt\/gfl307","article-title":"Arterial wave reflections and mortality in haemodialysis patients\u2013only relevant in elderly, cardiovascularly compromised?","volume":"21","author":"Covic","year":"2006","journal-title":"Nephrol Dial Transplant"},{"key":"10.1038\/ki.2014.69_bb0195","doi-asserted-by":"crossref","first-page":"S88","DOI":"10.1046\/j.1523-1755.63.s84.25.x","article-title":"Inflammation, arteriosclerosis, and cardiovascular therapy in hemodialysis patients","volume":"84","author":"London","year":"2003","journal-title":"Kidney Int Suppl"},{"key":"10.1038\/ki.2014.69_bb0200","doi-asserted-by":"crossref","first-page":"987","DOI":"10.1161\/01.CIR.103.7.987","article-title":"Impact of aortic stiffness attenuation on survival of patients in end-stage renal failure","volume":"103","author":"Guerin","year":"2001","journal-title":"Circulation"},{"key":"10.1038\/ki.2014.69_bb0205","doi-asserted-by":"crossref","first-page":"c31","DOI":"10.1159\/000210572","article-title":"Effects of angiotensin II type 1 receptor blocker on blood pressure variability and cardiovascular remodeling in hypertensive patients on chronic peritoneal dialysis","volume":"112","author":"Shigenaga","year":"2009","journal-title":"Nephron Clin Pract"},{"key":"10.1038\/ki.2014.69_bb0210","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1016\/j.atherosclerosis.2009.04.005","article-title":"Effect of losartan on ambulatory short-term blood pressure variability and cardiovascular remodeling in hypertensive patients on hemodialysis","volume":"207","author":"Mitsuhashi","year":"2009","journal-title":"Atherosclerosis"},{"key":"10.1038\/ki.2014.69_bb0215","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1093\/ndt\/gfp417","article-title":"Inflammation, overhydration and cardiac biomarkers in haemodialysis patients: a longitudinal study","volume":"25","author":"Jacobs","year":"2010","journal-title":"Nephrol Dial Transplant"},{"key":"10.1038\/ki.2014.69_bb0220","doi-asserted-by":"crossref","first-page":"583","DOI":"10.1007\/s11255-011-0022-y","article-title":"Randomized trial of bioelectrical impedance analysis vs. clinical criteria for guiding ultrafiltration in hemodialysis patients: effects on blood pressure, hydration status, and arterial stiffness","volume":"44","author":"Onofriescu","year":"2012","journal-title":"Int Urol Nephrol"},{"key":"10.1038\/ki.2014.69_bb0225","doi-asserted-by":"crossref","first-page":"33","DOI":"10.2310\/JIM.0b013e318194f44b","article-title":"Natriuretic peptides in chronic kidney disease and during renal replacement therapy: an update","volume":"57","author":"Khalifeh","year":"2009","journal-title":"J Investig Med"},{"key":"10.1038\/ki.2014.69_bb0230","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1038\/sj.ki.5002140","article-title":"Measuring risk in end-stage renal disease: is N-terminal pro brain natriuretic peptide a useful marker?","volume":"71","author":"Rosner","year":"2007","journal-title":"Kidney Int"},{"key":"10.1038\/ki.2014.69_bb0235","doi-asserted-by":"crossref","first-page":"1321","DOI":"10.1056\/NEJM199904293401704","article-title":"Reduction of sympathetic hyperactivity by enalapril in patients with chronic renal failure","volume":"340","author":"Ligtenberg","year":"1999","journal-title":"N Engl J Med"},{"key":"10.1038\/ki.2014.69_bb0240","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1111\/j.1440-1797.2006.00680.x","article-title":"Influence of angiotensin converting enzyme inhibitor treatment on cardiac autonomic modulation in patients receiving haemodialysis","volume":"11","author":"Ondocin","year":"2006","journal-title":"Nephrology (Carlton)"},{"key":"10.1038\/ki.2014.69_bb0245","doi-asserted-by":"crossref","first-page":"69","DOI":"10.5507\/bp.2004.012","article-title":"Telmisartan in the treatment of hypertension in patients with chronic renal insufficiency","volume":"148","author":"Weinbergova","year":"2004","journal-title":"Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub"},{"key":"10.1038\/ki.2014.69_bb0250","doi-asserted-by":"crossref","first-page":"1568","DOI":"10.1111\/j.1523-1755.2004.00552.x","article-title":"Sympathetic hyperactivity in chronic kidney disease: pathogenesis, clinical relevance, and treatment","volume":"65","author":"Neumann","year":"2004","journal-title":"Kidney Int"},{"key":"10.1038\/ki.2014.69_bb0255","doi-asserted-by":"crossref","first-page":"1407","DOI":"10.1111\/j.1540-8159.2010.02841.x","article-title":"A quantitative systematic review of normal values for short-term heart rate variability in healthy adults","volume":"33","author":"Nunan","year":"2010","journal-title":"Pacing Clin Electrophysiol"},{"key":"10.1038\/ki.2014.69_bb0260","doi-asserted-by":"crossref","first-page":"668","DOI":"10.1111\/j.1523-1755.2005.67123.x","article-title":"Plasma metanephrines in renal failure","volume":"67","author":"Eisenhofer","year":"2005","journal-title":"Kidney Int"},{"key":"10.1038\/ki.2014.69_bb0265","doi-asserted-by":"crossref","first-page":"2003","DOI":"10.2215\/CJN.02700311","article-title":"Toward a definition of masked hypertension and white-coat hypertension among hemodialysis patients","volume":"6","author":"Agarwal","year":"2011","journal-title":"Clin J Am Soc Nephrol"},{"key":"10.1038\/ki.2014.69_bb0270","doi-asserted-by":"crossref","first-page":"957","DOI":"10.1053\/j.ajkd.2012.12.017","article-title":"Effect of fluid management guided by bioimpedance spectroscopy on cardiovascular parameters in hemodialysis patients: a randomized controlled trial","volume":"61","author":"Hur","year":"2013","journal-title":"Am J Kidney Dis"},{"key":"10.1038\/ki.2014.69_bb0275","doi-asserted-by":"crossref","first-page":"861","DOI":"10.1053\/j.ajkd.2013.03.004","article-title":"Bioimpedance technology and optimal fluid management","volume":"61","author":"Daugirdas","year":"2013","journal-title":"Am J Kidney Dis"},{"key":"10.1038\/ki.2014.69_bb0280","doi-asserted-by":"crossref","first-page":"610","DOI":"10.1016\/S0009-9236(97)90080-1","article-title":"The pharmacokinetics of irbesartan in renal failure and maintenance hemodialysis","volume":"62","author":"Sica","year":"1997","journal-title":"Clin Pharmacol Ther"},{"key":"10.1038\/ki.2014.69_bb0285","doi-asserted-by":"crossref","first-page":"246","DOI":"10.1002\/j.1552-4604.1998.tb04422.x","article-title":"Pharmacokinetics and pharmacodynamics of irbesartan in healthy subjects","volume":"38","author":"Marino","year":"1998","journal-title":"J Clin Pharmacol"},{"key":"10.1038\/ki.2014.69_bb0290","doi-asserted-by":"crossref","first-page":"594","DOI":"10.1093\/ndt\/gfm470","article-title":"Reproducibility of pulse-wave analysis and pulse-wave velocity determination in chronic kidney disease","volume":"23","author":"Frimodt-Moller","year":"2008","journal-title":"Nephrol Dial Transplant"},{"key":"10.1038\/ki.2014.69_bb0295","unstructured":"Atcor Medical Technical Note No: 14 Assuring Quality of Pulse Wave Analysis Measurementshttp:\/\/atcormedical.com\/technical_notes.html"},{"key":"10.1038\/ki.2014.69_bb0300","doi-asserted-by":"crossref","first-page":"594","DOI":"10.1038\/jhh.2011.76","article-title":"Assessment of differences between repeated pulse wave velocity measurements in terms of \u2018bias\u2019 in the extrapolated cardiovascular risk and the classification of aortic stiffness: is a single PWV measurement enough?","volume":"26","author":"Papaioannou","year":"2011","journal-title":"J Hum Hypertens"},{"key":"10.1038\/ki.2014.69_bb0305","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1097\/HJH.0b013e32834fa8b0","article-title":"Expert consensus document on the measurement of aortic stiffness in daily practice using carotid-femoral pulse wave velocity","volume":"30","author":"Van Bortel","year":"2012","journal-title":"J Hypertens"},{"key":"10.1038\/ki.2014.69_bb0310","doi-asserted-by":"crossref","first-page":"2377","DOI":"10.1097\/HJH.0b013e3283313a8a","article-title":"Distance measurements for the assessment of carotid to femoral pulse wave velocity","volume":"27","author":"Vermeersch","year":"2009","journal-title":"J Hypertens"},{"key":"10.1038\/ki.2014.69_bb0315","doi-asserted-by":"crossref","first-page":"2338","DOI":"10.1093\/eurheartj\/ehq165","article-title":"Determinants of pulse wave velocity in healthy people and in the presence of cardiovascular risk factors: \u2018establishing normal and reference values\u2019","volume":"31","author":"Mattace-Raso","year":"2010","journal-title":"Eur Heart J"},{"key":"10.1038\/ki.2014.69_bb0320","doi-asserted-by":"crossref","first-page":"1440","DOI":"10.1016\/j.echo.2005.10.005","volume":"18","author":"Lang","year":"2005","journal-title":"J Am Soc Echocardiogr"},{"key":"10.1038\/ki.2014.69_bb0325","doi-asserted-by":"crossref","first-page":"354","DOI":"10.1093\/oxfordjournals.eurheartj.a014868","article-title":"Heart rate variability: standards of measurement, physiological interpretation, and clinical use. Task Force of the European Society of Cardiology and the North American Society of Pacing and Electrophysiology","volume":"17","author":"Malik","year":"1996","journal-title":"Eur Heart J"},{"key":"10.1038\/ki.2014.69_bb0330","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1089\/152091501750220028","article-title":"Heart rate variability measurement in diabetic neuropathy: review of methods","volume":"3","author":"Risk","year":"2001","journal-title":"Diabetes Technol Ther"},{"key":"10.1038\/ki.2014.69_bb0335","unstructured":"Roche Diagnostics N-terminal pro B-type natriuretic peptide product sheet (version 7)."},{"key":"10.1038\/ki.2014.69_bb0340","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1080\/00365519909168341","article-title":"Development of a novel, N-terminal-proBNP (NT-proBNP) assay with a low detection limit","volume":"230","author":"Karl","year":"1999","journal-title":"Scand J Clin Lab Invest Suppl"},{"key":"10.1038\/ki.2014.69_bb0345","unstructured":"Radioimmunoassay (RIA) for the high-sensitive quantitative determination of Adrenaline (Epinephrine) and Noradrenaline (Norepinephrine) in plasmahttp:\/\/www.ldn.de\/sites\/default\/files\/downloads\/MSDS%20BA%20R-4500%202-CAT%20Plasma%20RIA%20%20High%20Sensitive%20en.pdf"}],"container-title":["Kidney International"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0085253815303227?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0085253815303227?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2022,3,31]],"date-time":"2022-03-31T01:19:57Z","timestamp":1648689597000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0085253815303227"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,9]]},"references-count":68,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2014,9]]}},"alternative-id":["S0085253815303227"],"URL":"https:\/\/doi.org\/10.1038\/ki.2014.69","relation":{},"ISSN":["0085-2538"],"issn-type":[{"value":"0085-2538","type":"print"}],"subject":[],"published":{"date-parts":[[2014,9]]}}}